• The High-Intensity Focused Ultrasound market is estimated at USD 1.45 billion in 2025 and is projected to reach USD 3.05 billion by 2034. Growth is anchored in the rising cancer burden, growing demand for non-invasive and incisionless therapy, and expanding clinical applications across prostate cancer, neurology, uterine fibroids, and aesthetics.

• The global High-Intensity Focused Ultrasound market is growing at a CAGR of 8.6% during the forecast period from 2026 to 2034.

• By application, the oncology segment dominated the High-Intensity Focused Ultrasound market with a 52% share in 2025.

• By guidance technology, the ultrasound-guided HIFU segment dominated the High-Intensity Focused Ultrasound market with a 58% share in 2025.

• By method, the non-invasive segment dominated the High-Intensity Focused Ultrasound market with a 74% share in 2025.

• By end user, the hospitals segment dominated the High-Intensity Focused Ultrasound market with a 43% share in 2025.

• North America dominated the global High-Intensity Focused Ultrasound market revenue with a 41% share in 2025, representing the highest regional market share globally.

High-intensity focused ultrasound (HIFU) is a non-invasive, incisionless therapeutic technology that focuses ultrasonic energy onto a targeted point deep within the body to raise tissue temperature and precisely ablate diseased tissue while sparing surrounding structures. Guided in real time by either ultrasound imaging or magnetic resonance imaging, HIFU delivers thermal ablation without incisions or ionizing radiation, enabling outpatient treatment with rapid recovery. The technology is used across a widening range of clinical applications, including focal ablation of localized prostate cancer, treatment of uterine fibroids, neurological indications such as essential tremor and Parkinson's disease through transcranial magnetic-resonance-guided focused ultrasound, tumor ablation, and aesthetic and dermatological procedures such as skin tightening. The market spans ultrasound-guided and magnetic-resonance-guided systems, non-invasive and minimally invasive approaches, and end users including hospitals, ambulatory surgical centers, specialty clinics, and research institutes. Anchored by systems such as Sonablate, Focal One, Exablate, and TULSA-PRO, and propelled by the rising cancer burden, demand for organ-sparing therapy, neurological expansion, and improving reimbursement, HIFU has emerged as one of the most promising frontiers in non-invasive, image-guided therapeutics.

High-Intensity Focused Ultrasound Market Key Growth Drivers

• The rising global cancer burden is driving demand for non-invasive tumor ablation, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050.

• Growing demand for non-invasive and organ-sparing therapy, which avoids incisions, ionizing radiation, and the morbidity of conventional surgery, is expanding adoption across oncology and other indications.

• Expanding neurological applications, including magnetic-resonance-guided focused ultrasound for essential tremor and Parkinson's disease, are opening a high-growth frontier for the technology.

• A wave of regulatory clearances and approvals, including new editions of robotic prostate HIFU systems and neurological indications, is broadening the addressable market.

• Improving reimbursement, including favorable coverage recommendations for magnetic-resonance-guided focused ultrasound in several markets, is supporting clinical adoption.

• Rising prevalence of prostate cancer, uterine fibroids, and movement disorders, alongside aging populations, is enlarging the treatable patient pool.

• The convergence of cancer burden, non-invasive therapy demand, neurological expansion, and regulatory and reimbursement progress is expected to sustain strong growth in the market through 2034.

Key Companies in High-Intensity Focused Ultrasound Market

The competitive landscape is led by the following active developers and providers:

• Insightec Ltd.

• EDAP TMS S.A.

• Profound Medical Corp.

• SonaCare Medical, LLC

• Chongqing Haifu Medical Technology Co., Ltd.

• Theraclion S.A.

• Alpinion Medical Systems Co., Ltd.

• Koninklijke Philips N.V.

• FUSMobile Inc.

• Arrayus Technologies Inc.

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies, where relevant to the market assessment.

High-Intensity Focused Ultrasound Market Size

The following snapshot summarizes the principal report metrics for the High-Intensity Focused Ultrasound market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

 

Factors Contributing to the Growth of the High-Intensity Focused Ultrasound Market

Market Drivers

Rising Global Cancer Burden and Demand for Tumor Ablation

The most powerful driver of the HIFU market is the rising global cancer burden and the strong demand for non-invasive tumor ablation. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, and cancer remains a leading cause of death worldwide. HIFU offers precise, incisionless thermal ablation of tumors, most prominently in localized prostate cancer, where focal therapy can destroy either the tumor or a portion of the gland while sparing surrounding tissue, reducing the incontinence, erectile dysfunction, and bowel morbidity associated with whole-gland surgery or radiation. The technology is also applied to uterine fibroids, liver, breast, pancreatic, and other tumors, and to bone metastases for pain palliation. As cancer incidence climbs with aging populations and improving diagnosis, and as patients and physicians increasingly favor organ-sparing options, demand for HIFU tumor ablation expands, anchoring market growth through the forecast period. 

Growing Demand for Non-Invasive and Organ-Sparing Therapy

Growing demand for non-invasive, organ-sparing therapy is a central growth engine. HIFU delivers ablative energy through the skin and mucosa without incisions or ionizing radiation, enabling outpatient treatment, rapid recovery, minimal blood loss, and low complication rates compared with conventional surgery and radiotherapy. For localized prostate cancer, focal HIFU preserves continence and potency far better than whole-gland treatment, and for uterine fibroids and other conditions it offers a uterus-sparing, day-case alternative to hysterectomy or open surgery. Patients increasingly seek treatments that minimize hospitalization, scarring, and long-term side effects, and health systems value the reduced complications and faster recovery that lower overall care costs. The repeatable and well-tolerated nature of HIFU supports its integration into outpatient and ambulatory settings. As preference for minimally invasive, quality-of-life-preserving therapy grows across specialties, demand for HIFU expands, reinforcing market growth across the forecast period. 

Expanding Neurological Applications

Expanding neurological applications represent the fastest-growing frontier for HIFU. Transcranial magnetic-resonance-guided focused ultrasound enables incisionless ablation of precise targets deep within the brain, and it has become an established treatment for medication-refractory essential tremor and tremor-dominant Parkinson's disease, delivering immediate, measurable improvement without opening the skull. Real-time magnetic resonance thermometry allows clinicians to monitor and confirm ablation during the procedure, improving safety and precision. Research is rapidly extending focused ultrasound into additional neurological indications, including other movement disorders, neuropathic pain, and, in investigational settings, the transient opening of the blood-brain barrier to deliver therapeutics and neuromodulation. Growing clinical evidence, expanding treatment centers, and favorable reimbursement recommendations in several markets are accelerating neurological adoption. As the neurological application set broadens and evidence accumulates, this segment drives disproportionate growth, reinforcing market expansion across the forecast period. 

Regulatory Clearances and Expanding Approved Indications

Accelerating regulatory clearances and an expanding set of approved indications are broadening the HIFU market. Robotic prostate HIFU systems have secured successive clearances, including new editions with advanced ultrasound imaging and streamlined workflows, and magnetic-resonance-guided systems hold clearances for prostate ablation, uterine fibroids, bone-metastasis pain palliation, and neurological indications such as essential tremor. New device generations add artificial-intelligence-assisted targeting, real-time thermometry, and improved imaging integration, while ongoing pivotal studies pursue additional indications such as varicose veins and whole-gland prostate treatment. Each clearance expands the treatable population, supports reimbursement, and encourages investment and adoption by hospitals and clinics. As manufacturers pursue new indications and next-generation systems clear regulatory review, the addressable market widens, driving demand across the forecast period. 

Improving Reimbursement and Health-System Adoption

Improving reimbursement and growing health-system adoption are strengthening the commercial foundation of HIFU. Reimbursement has historically been a barrier, but coverage is expanding, with favorable recommendations for magnetic-resonance-guided focused ultrasound in essential tremor emerging in several markets, including a positive reimbursement recommendation from the Dutch Healthcare Institute, and growing coverage for focal prostate therapy. As clinical evidence accumulates and outcomes data demonstrate cost-effectiveness through reduced complications and shorter recovery, payers and health systems are increasingly willing to cover HIFU procedures. Hospitals and specialized centers are investing in HIFU systems to differentiate their offerings and meet patient demand for non-invasive options, and leading institutions are adopting the technology across urology, neurology, and gynecology. As reimbursement broadens and adoption deepens, the economic case for HIFU strengthens, supporting sustained market growth across the forecast period. 

Rising Prevalence of Target Conditions and Aging Populations

The rising prevalence of the conditions HIFU treats, combined with aging populations, is enlarging the treatable patient pool. Prostate cancer is among the most common cancers in men and its incidence rises sharply with age, uterine fibroids affect a large share of women of reproductive age, and movement disorders such as essential tremor and Parkinson's disease become more common with age and affect millions worldwide. As populations age, particularly in high-income and rapidly aging middle-income countries, the number of patients eligible for HIFU across urology, gynecology, and neurology grows steadily. Greater awareness of non-invasive options, improved diagnosis, and rising demand for quality-of-life-preserving treatment further expand the addressable population. As demographic trends increase the burden of these conditions, demand for HIFU therapy grows, reinforcing market expansion across the forecast period. 

Technological Advances in Imaging, Robotics, and AI

Technological advances in imaging, robotics, and artificial intelligence are enhancing the precision, safety, and reach of HIFU. Modern systems integrate advanced ultrasound and magnetic resonance imaging, real-time thermometry, robotic delivery, and artificial-intelligence-assisted planning and targeting, improving ablation accuracy and treatment evaluation. Fusion of ultrasound with magnetic resonance and molecular imaging enhances tumor visualization and targeting, while robotic focal systems streamline treatment planning and delivery. Emerging capabilities, including histotripsy-adjacent mechanical ablation, neuromodulation, and investigational blood-brain-barrier opening, are extending the therapeutic potential of focused ultrasound. These advances reduce procedure times, improve outcomes, and expand the range of treatable conditions, allowing manufacturers to differentiate their systems and attract clinical adoption. As imaging, robotics, and artificial intelligence continue to advance, they broaden HIFU's clinical utility and reinforce the market's long-term growth trajectory across the forecast period. 

Market Restraints

Despite strong momentum, the HIFU market faces material constraints. High system and procedure costs are a primary barrier, as HIFU platforms, particularly magnetic-resonance-guided systems that require access to magnetic resonance imaging suites, involve substantial capital investment and operating expense, limiting adoption to well-resourced hospitals and specialized centers. Reimbursement, although improving, remains uneven and immature across many geographies and indications, and the absence of broad or consistent coverage constrains patient access and the return on investment for providers. Long treatment times for certain applications, particularly some magnetic-resonance-guided procedures, reduce throughput and limit the number of patients treated per system. Clinical and anatomical limitations also apply, as HIFU is not suitable for all tumor locations or patient anatomies, patient movement can affect targeting, and some tissues and bony structures impede energy delivery, while long-term comparative outcomes data against established therapies are still maturing for several indications. A shortage of trained operators and specialized centers limits capacity, and awareness among referring physicians and patients remains uneven. Competition from other minimally invasive and ablative modalities, including cryotherapy, radiofrequency ablation, stereotactic radiotherapy, and emerging histotripsy, intensifies the landscape. Regulatory pathways for new indications are lengthy and evidence-intensive. Together, these cost, reimbursement, throughput, clinical, and awareness barriers temper the pace of growth, even as the underlying drivers of non-invasive therapy demand and clinical expansion remain firmly intact.

 

High-Intensity Focused Ultrasound Market Segment Analysis

The High-Intensity Focused Ultrasound Market by Application (Oncology, Uterine Fibroids, Neurological Disorders, Aesthetics and Dermatology, Others), Guidance Technology (Ultrasound-Guided HIFU, Magnetic-Resonance-Guided HIFU), Method (Non-Invasive, Minimally Invasive), End User (Hospitals, Ambulatory Surgical Centers and Specialty Clinics, Diagnostic and Imaging Centers, Research Institutes), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Application

Dominant Subsegment: Oncology. The oncology category is expected to dominate the market.

Dominant:  Oncology ~ 52%

The oncology segment accounted for 52% of the High-Intensity Focused Ultrasound market in 2025. Oncology is the leading application because HIFU's core clinical value lies in the non-invasive, organ-sparing ablation of tumors, most prominently localized prostate cancer. Focal HIFU destroys the tumor or a portion of the prostate while preserving continence and potency far better than whole-gland surgery or radiation, and dedicated systems such as Sonablate, Focal One, Exablate Prostate, and TULSA-PRO anchor a large and growing prostate-cancer segment. Beyond the prostate, HIFU ablates liver, breast, pancreatic, kidney, and other tumors and palliates bone-metastasis pain, broadening its oncology footprint. The rising global cancer burden, growing preference for organ-sparing therapy, and expanding clinical evidence reinforce the segment's dominance. Neurological disorders form the fastest-growing application, while uterine fibroids and aesthetic and dermatological procedures are large and established segments. Nonetheless, the scale, clinical value, and breadth of tumor-ablation applications secure the leadership of oncology across the forecast period.

By Guidance Technology

Dominant Subsegment: Ultrasound-Guided HIFU. The ultrasound-guided HIFU category is expected to dominate the market.

Dominant:  Ultrasound-Guided HIFU ~ 58%

The ultrasound-guided HIFU segment accounted for 58% of the High-Intensity Focused Ultrasound market in 2025. Ultrasound-guided HIFU is the leading guidance technology because it is more widely deployed, more affordable, and more accessible than magnetic-resonance-guided systems, which require costly access to magnetic resonance imaging suites. Ultrasound guidance provides real-time imaging integrated directly into the treatment system, enabling efficient, lower-cost procedures in urology, gynecology, and general tumor ablation, and it underpins widely used prostate systems such as Sonablate and Focal One as well as many fibroid and tumor-ablation platforms. Its lower capital and operating costs support broader adoption across hospitals, ambulatory centers, and clinics. Magnetic-resonance-guided HIFU is a large and fast-growing segment, essential for neurological applications and valued for superior soft-tissue visualization and real-time thermometry, exemplified by Exablate Neuro and TULSA-PRO. While magnetic-resonance-guided systems grow rapidly in neurology, the accessibility, affordability, and installed base of ultrasound-guided HIFU secure its leadership across the forecast period.

By Method

Dominant Subsegment: Non-Invasive. The non-invasive category is expected to dominate the market.

Dominant:  Non-Invasive ~ 74%

The non-invasive segment accounted for 74% of the High-Intensity Focused Ultrasound market in 2025. Non-invasive HIFU is the dominant method because the technology's defining advantage is the delivery of ablative energy through the skin, mucosa, or skull without any incision, needle, or ionizing radiation. Transcranial neurological treatment, transrectal prostate ablation, transabdominal fibroid and tumor treatment, and aesthetic skin procedures are all delivered non-invasively, enabling outpatient care, rapid recovery, and low complication rates that drive patient and physician preference. This fully non-invasive profile is the central reason HIFU is adopted over conventional surgery and is the basis of its value proposition across oncology, neurology, gynecology, and aesthetics. Minimally invasive approaches, including certain transurethral and catheter-based configurations used in some prostate and vascular applications, form a smaller but important segment that extends HIFU into specific anatomies. Nonetheless, the incisionless, radiation-free profile that defines the technology secures the clear leadership of the non-invasive method across the forecast period.

By End User

Dominant Subsegment: Hospitals. The hospitals category is expected to dominate the market.

Dominant:  Hospitals ~ 43%

The hospitals segment accounted for 43% of the High-Intensity Focused Ultrasound market in 2025. Hospitals are the leading end user because HIFU systems, particularly magnetic-resonance-guided platforms, require substantial capital investment, specialized infrastructure, and multidisciplinary teams that large hospitals and academic medical centers are best positioned to provide. Hospitals treat the most complex cases across urology, neurology, and gynecology, integrate HIFU into comprehensive cancer and neurology programs, and serve as the primary sites for new indications and clinical studies, anchoring their large share. Leading institutions adopt HIFU to differentiate their offerings and meet patient demand for non-invasive options. Ambulatory surgical centers and specialty clinics form a large and fast-growing segment, particularly for prostate focal therapy and aesthetic procedures that suit outpatient, lower-cost settings, while diagnostic and imaging centers and research institutes support magnetic-resonance-guided treatment and clinical development. While ambulatory and specialty settings grow quickly, the infrastructure, case complexity, and clinical breadth of hospitals secure their leadership across the forecast period.

 

High-Intensity Focused Ultrasound Market Region Analysis

Dominant Region: North America

North America accounted for 41% of the global High-Intensity Focused Ultrasound market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced healthcare infrastructure, high adoption of innovative medical technology, strong reimbursement momentum for neurological and prostate applications, and the presence of leading HIFU developers and treatment centers, particularly in the United States. North America leads in magnetic-resonance-guided focused ultrasound for essential tremor and Parkinson's disease, in robotic focal prostate therapy with systems such as Focal One and Sonablate, and in clinical research expanding HIFU into new indications. The region benefits from high healthcare spending, a large base of academic medical centers and specialized treatment sites, active clinical trials, and growing payer coverage. Strong infrastructure, technology adoption, and reimbursement progress anchor the region's continued leadership across the forecast period.

Dominant:  North America ~ 41% (Largest)

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the High-Intensity Focused Ultrasound market. The region's elevated CAGR is driven by a large and rising cancer burden, expanding healthcare access and investment, growing adoption of non-invasive therapy, and strong regional developers across China, Japan, South Korea, and India. China is a major center of HIFU innovation and use, home to Chongqing Haifu Medical Technology, a pioneer of ultrasound-guided HIFU for tumor ablation, and the region benefits from large patient populations, government investment in advanced healthcare, and expanding treatment capacity. Rising prostate cancer and uterine fibroid prevalence, growing neurological application, and increasing adoption of aesthetic HIFU further accelerate demand. The combination of high disease burden, healthcare investment, and local innovation positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 41% of the global High-Intensity Focused Ultrasound market revenue in 2025. The United States dominates on the strength of advanced infrastructure, high technology adoption, growing reimbursement for neurological and prostate applications, a dense base of treatment centers, and active clinical research, while Canada contributes through neurological and prostate HIFU adoption and the presence of Profound Medical.

Europe

Europe is a large and advanced regional market, led by Germany, the United Kingdom, France, Italy, and Spain. Growth is supported by strong adoption of focal prostate therapy and neurological focused ultrasound, active clinical research, the presence of developers such as EDAP TMS and Theraclion, and expanding reimbursement, including favorable coverage recommendations for magnetic-resonance-guided focused ultrasound in several countries.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a large and rising cancer burden, expanding healthcare access and investment, and strong regional developers across China, Japan, South Korea, and India. Chongqing Haifu anchors ultrasound-guided tumor ablation, while growing prostate, fibroid, neurological, and aesthetic applications and large patient populations broaden adoption across the region.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging contributor. Rising cancer and chronic-disease burden, growing interest in non-invasive therapy, and adoption of prostate and aesthetic HIFU in premium private centers, particularly in the Gulf states, are creating early demand, while broader adoption awaits stronger reimbursement, infrastructure, and trained-operator capacity across these markets over the forecast period.

 

High-Intensity Focused Ultrasound Market Competitive Landscape

The High-Intensity Focused Ultrasound market is classified as Moderately Concentrated. A group of specialized leaders, including Insightec, EDAP TMS, Profound Medical, SonaCare Medical, and Chongqing Haifu, holds a substantial share across the principal application areas of neurology, prostate, and tumor ablation, while a broad field of regional and application-focused developers, including Theraclion, Alpinion, FUSMobile, Arrayus, and aesthetic-HIFU providers, competes across indications and geographies, keeping the market competitive and innovation-driven.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with application-specialized leaders alongside a broad field of regional and indication-focused developers.

• Leading players: Insightec leads neurology, EDAP TMS and SonaCare lead prostate, Profound Medical leads transurethral MR-guided ablation, and Chongqing Haifu leads tumor ablation.

• Geographic reach: Players span North America, Europe, and Asia-Pacific, with Chongqing Haifu strong in China and Insightec and EDAP TMS globally established.

• Product portfolio strength: Systems span ultrasound-guided and magnetic-resonance-guided platforms across prostate, neurology, fibroids, tumor ablation, and aesthetics.

• Pipeline and indication expansion: Ongoing pivotal studies in neurology, whole-gland prostate treatment, varicose veins, and oncology are decisive competitive assets.

• Strategic partnerships: Collaborations with academic centers and imaging partners, such as Insightec with Mayo Clinic and Sonablate with Siemens Healthineers, extend reach.

• Regulatory strength: Successive FDA and international clearances across prostate, neurological, and fibroid indications differentiate leading players.

• Reimbursement progress: Favorable coverage recommendations for neurological focused ultrasound and growing focal-prostate coverage strengthen commercial positioning.

• Innovation focus: Robotic focal therapy, AI-assisted targeting, real-time thermometry, imaging fusion, histotripsy-adjacent ablation, and neuromodulation.

 

High-Intensity Focused Ultrasound Market Recent Developmental Activities

In November 2025, EDAP TMS S.A., received FDA 510(k) clearance for the latest edition of its Focal One Robotic HIFU system, adding advanced ultrasound imaging, streamlined treatment planning, an optimized user interface, and support for artificial-intelligence-driven ablation-visualization algorithms. Strategic significance: Strengthened EDAP's leadership in robotic focal prostate therapy and advanced AI-assisted HIFU.

In 2025, EDAP TMS S.A., launched the Focal One i at the American Urological Association Annual Meeting, integrating enhanced imaging and workflow capabilities for robotic focal prostate cancer therapy. Strategic significance: Refreshed EDAP's flagship platform and reinforced its position in ultrasound-guided prostate HIFU.

In 2024, Insightec Ltd., advanced its Exablate Neuro platform for magnetic-resonance-guided focused ultrasound treatment of medication-refractory essential tremor and tremor-dominant Parkinson's disease, incorporating real-time thermometry and improved targeting. Strategic significance: Reinforced Insightec's leadership in incisionless neurological HIFU.

In January 2024, Insightec Ltd., received a positive reimbursement recommendation from the Dutch Healthcare Institute for magnetic-resonance-guided focused ultrasound treatment of essential tremor in the Netherlands. Strategic significance: Advanced European reimbursement for neurological HIFU and supported broader access.

In 2024, Insightec Ltd. (with Mayo Clinic), expanded its collaboration on neurological focused ultrasound to advance research and clinical application across movement disorders and additional indications. Strategic significance: Deepened clinical evidence and academic partnership underpinning neurological HIFU expansion.

In 2024, Profound Medical Corp., advanced its TULSA-PRO transurethral magnetic-resonance-guided ablation system for prostate tissue, including progress in a pivotal whole-gland study and regulatory milestones. Strategic significance: Extended magnetic-resonance-guided prostate ablation toward broader whole-gland indications.

In January 2025, Theraclion S.A., reported completion of the FDA pivotal study of SONOVEIN, its non-invasive HIFU therapy for varicose veins, with a marketing authorization application planned for the second half of 2025 and FDA approval anticipated in the first half of 2026. Strategic significance: Advanced HIFU into vascular indications and toward United States market entry.

In 2024, SonaCare Medical, LLC, advanced its next-generation Sonablate prostate HIFU platform with enhanced imaging, and pursued imaging-integration collaboration to strengthen its focal-therapy offering. Strategic significance: Reinforced SonaCare's position in ultrasound-guided focal prostate HIFU.

In 2024, Chongqing Haifu Medical Technology Co., Ltd., expanded its ultrasound-guided HIFU systems for tumor ablation and uterine fibroids, advancing regulatory clearances and international reach. Strategic significance: Reinforced Chongqing Haifu's leadership in ultrasound-guided tumor ablation and Asia-Pacific growth.

In August 2024, FUSMobile Inc., advanced its Neurolyser XR focused ultrasound platform for image-guided ablation to treat chronic pain conditions such as facet-joint arthritis. Strategic significance: Extended focused ultrasound into interventional pain management and broadened application diversity.

In January 2024, Kokilaben Dhirubhai Ambani Hospital, adopted HIFU technology for minimally invasive treatment of localized prostate cancer in India. Strategic significance: Illustrated growing Asia-Pacific hospital adoption of prostate HIFU and expanding regional access.

In 2024, Arrayus Technologies Inc., advanced its magnetic-resonance-guided focused ultrasound platform for oncology and other applications, progressing clinical and technology development. Strategic significance: Added an emerging magnetic-resonance-guided competitor advancing HIFU across oncology indications.

 

High-Intensity Focused Ultrasound Market Segmentation

High-Intensity Focused Ultrasound Market by Application

• Oncology

• Prostate Cancer

• Liver, Breast, and Pancreatic Tumors

• Bone Metastasis Palliation

• Other Tumors

• Uterine Fibroids

• Neurological Disorders

• Aesthetics and Dermatology

• Others

High-Intensity Focused Ultrasound Market by Guidance Technology

• Ultrasound-Guided HIFU (USgHIFU)

• Magnetic-Resonance-Guided HIFU (MRgHIFU)

High-Intensity Focused Ultrasound Market by Method

• Non-Invasive

• Minimally Invasive

High-Intensity Focused Ultrasound Market by End User

• Hospitals

• Ambulatory Surgical Centers and Specialty Clinics

• Diagnostic and Imaging Centers

• Research Institutes

High-Intensity Focused Ultrasound Market by Geography

• North America High-Intensity Focused Ultrasound Market

• United States High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Canada High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Mexico High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Europe High-Intensity Focused Ultrasound Market

• Germany High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• United Kingdom High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• France High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Italy High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Spain High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Rest of Europe High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Asia-Pacific High-Intensity Focused Ultrasound Market

• China High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Japan High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• India High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• South Korea High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Australia High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Rest of Asia-Pacific High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Rest of the World (RoW) High-Intensity Focused Ultrasound Market

• Middle East High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• Africa High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

• South America High-Intensity Focused Ultrasound Market Size in USD million (2023-2034)

 

High-Intensity Focused Ultrasound Market Recent Industry Trends and Milestones (2023-2026)

 

High-Intensity Focused Ultrasound Market Startup Funding and Investment Trends

Investment in the focused ultrasound ecosystem has concentrated on neurological applications, robotic and magnetic-resonance-guided systems, and expansion into new indications. Because several leading players are established or public companies, investment activity blends venture funding with corporate and clinical development. The following companies illustrate recent investment and development activity and technology focus.

Capital and development activity are concentrated on neurology, magnetic-resonance-guided systems, and expansion into new indications. Insightec, a large late-stage private company, leads neurological focused ultrasound with Exablate Neuro, while publicly listed Theraclion and Profound Medical advance vascular and prostate applications with SONOVEIN and TULSA-PRO. Emerging players such as Arrayus Technologies and FUSMobile pursue magnetic-resonance-guided oncology and image-guided pain applications, and established developers including EDAP TMS, SonaCare, and Chongqing Haifu invest in next-generation systems and new indications. Strategic partnerships with academic centers and imaging companies further support development. Collectively, these investments signal conviction that magnetic-resonance-guided neurology, robotic focal therapy, and expanding indications will define the next phase of competitive advantage in the global High-Intensity Focused Ultrasound market.

 

Key Takeaways from the High-Intensity Focused Ultrasound Market Report Study

• Market size analysis for the current high-intensity focused ultrasound market size (2025), and market forecast for 9 years (2026 to 2034).

• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.

• Key companies dominating the global high-intensity focused ultrasound market.

• Various opportunities available for competitors in the high-intensity focused ultrasound market space.

• What are the top-performing segments in 2025? How will these segments perform in 2034?

• Which are the top-performing regions and countries in the current high-intensity focused ultrasound market scenario?

• Which are the regions and countries where companies should concentrate their opportunities for high-intensity focused ultrasound market growth in the future?

Target audience who can benefit from this high-intensity focused ultrasound market report study 

• High-Intensity Focused Ultrasound product providers

• Research organizations and consulting companies

• High-Intensity Focused Ultrasound-related organizations, associations, forums, and other alliances

• Government and corporate offices

• Start-up companies, venture capitalists, and private equity firms

• Distributors and traders dealing in high-intensity focused ultrasound

• Various end-users who want to know more about the high-intensity focused ultrasound market and the latest technological developments in the high-intensity focused ultrasound market.